Eli Lilly’s Verzenio drug, when combined with endocrine therapy, showed a significant improvement in overall survival for patients with early high-risk breast cancer. The Phase 3 monarchE trial, involving 5,637 adults across 38 countries, found that the combination treatment led to a statistically significant and clinically meaningful increase in overall survival compared to therapy alone. Additionally, a 7-year analysis demonstrated sustained benefits in disease-free and relapse-free survival. The safety profile of Verzenio remained consistent with previous reports.

Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company that develops and markets human pharmaceuticals globally. While LLY shows potential as an investment, some believe that certain AI stocks offer greater upside potential and less risk. For those interested in undervalued AI stocks that could benefit from Trump-era tariffs and onshoring trends, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: Eli Lilly’s Verzenio Significantly Improves Overall Survival in Early Breast Cancer Patients